News News

July 1, 2021 Sirnaomics Secures $105 Million Series E Financing

Proceeds to Fund Development of Novel RNAi Therapeutics for Cancers, Viral Infections, Fibrosis, and Metabolic Diseases Sirnaomics…

June 30, 2021 Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancer

Company Expects to Report Interim Clinical Data of the Phase 2 in Second Half of 2021 Sirnaomics,…

June 24, 2021 Sirnaomics Doses First Patient in Phase 1 Clinical Study of STP705 for Treatment of Liver Cancer

Expects to Report Initial Clinical Data in Second Half of 2021 Sirnaomics, Inc., a biopharmaceutical company engaged…

June 16, 2021 Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic…

April 28, 2021 Sirnaomics Enters Partnership with Walvax Biotechnology to Co-Develop Its Antiviral RNAi Therapeutic Product Candidate STP702

Sirnaomics Biopharmaceuticals (Suzhou) Co. Ltd., a subsidiary of Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery…

April 26, 2021 Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer

Company Expects to Report Initial Clinical Data in Second Half of 2021 Sirnaomics, Inc., a biopharmaceutical company…

1 2 3 4 12